Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,750 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression Severe Clear all
Completed Phase 4 Interventional Results available

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Selegiline Transdermal System, Placebo
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • National City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

rTMS for MDD: 5.5cm Rule vs. F3 Targeting

NCT03378570
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Repetitive transcranial magnetic stimulation
Device
Lead sponsor
Nicholas Trapp
Other
Eligibility
18 Years to 90 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

NCT05165394
View directory record Official record
Conditions
Anhedonia, Major Depressive Disorder
Interventions
Placebo, NBI-1065846
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

Pharmacological Intervention Project (Fluoxetine)

NCT00027378
View directory record Official record
Conditions
Alcoholism, Depression
Interventions
fluoxetine (Prozac), Placebo plus Treatment As Usual
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 17, 2026, 9:30 AM EDT
Not yet recruiting Phase 4 Interventional

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

NCT07139106
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine hydrochloride infusion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

NCT06340958
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder (MDD)
Interventions
CLE-100, Placebo
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
La Jolla, California • Lafayette, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neural Components Underlying the Treatment of Adolescent Depression

NCT01717508
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

NCT00985725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Matching placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Imperial, California • Los Alamitos, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 9:30 AM EDT
Terminated Phase 3 Interventional

Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

NCT01156415
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AGO178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 71 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
95
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 17, 2026, 9:30 AM EDT
Not yet recruiting Phase 2 Interventional

Ketamine Treatment for PTSD and MDD in TBI

NCT06228391
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder, Traumatic Brain Injury
Interventions
IV ketamine, Midazolam
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional

Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness

NCT02334228
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Major Depressive Disorder
Interventions
In SHAPE Lifestyles, Health Club Membership and Education
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Concord, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional

The CARE (Collaborative Adolescent Running Experience) Project

NCT05837351
View directory record Official record
Conditions
Depression, Anxiety, Major Depressive Disorder, Bipolar Disorder
Interventions
Exercise -Running
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NCT01570972
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Genotype on LY2216684

NCT01460381
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
LY2216684, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms

NCT05317481
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide, Suicidal Ideation
Interventions
BE-SMART-DR, psychoeducational control comparator condition (CC)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
16 Years to 29 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression

NCT03363919
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NeuroStar TMS Therapy® System, NeuroStar XPLOR®
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 17, 2026, 9:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuronal Responses to Social Feedback in Major Depressive Disorder

NCT02180607
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Empower: tDCS for Major Depressive Disorder at Home

NCT05202119
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
Flow Neuroscience AB
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 9:30 AM EDT
Not yet recruiting No phase listed Observational

Using Integrated Care and Wearable Technology to Evaluate Outcomes of the Shields & Stripes Program for Veterans and First Responders

NCT07452900
View directory record Official record
Conditions
Holistic Care, Mental Health, Sleep, PTSD, Depression - Major Depressive Disorder, Anxiety, Resilience, Recovery, Occupation, Biometrics Measurement, Veteran, Quality of Life
Interventions
Not listed
Lead sponsor
Baylor University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

The Role Of Omega-3 Fatty Acids In Adolescent Depression

NCT00962598
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Omega 3 Fatty Acids, Corn oil
Drug · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 17, 2026, 9:30 AM EDT
Not listed Phase 4 Interventional

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

NCT03857581
View directory record Official record
Conditions
Psychosis, Substance Use Disorders
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 17, 2026, 9:30 AM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07161700
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 66 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Chino, California • Garden Grove, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

A Trial of AXS-05 in Patients With Major Depressive Disorder

NCT04019704
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 9:30 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 17, 2026, 9:30 AM EDT